descargar artículo completo - Revista Dental de Chile

Rev Dent Chile Vol 94 Nº1Bibliografía1. Bell CH, Kain Z. Manual de anestesia pediátrica. Segundaedición. 485-500. New Haven, Connecticut.Harcourt Brace 1999.2. Tobin J. Malignant hyperthermia and apparent heatstroke. JAMA.2001;286(2):168-9.3. Wappler F, Fiege M, Antz M, Schulte am EschJ.Hemodynamic and metabolic alterations in response tograded exercise in a patient susceptible to malignanthyperthermia. Anesthesiology 2000; 92: 268-72.4. Wingard DW. Malignant hyperthermia: A human stressSyndrome? Lancet.1974;12:1450-1.5. Denborough M. Malignant hyperthermia. Lancet 1998;352:1131-6.6. Gronert GA, Thompson RL, Onofrio BM. Humanmalignant hyperthermia: Awake episodes and correctionsby dantrolene. Anesth Analg. 1980; 59: 377-81.7. Nielsen C, Mazzone. Muscle pain after exercise. Lancet1999; 353: 1062.8. Wappler F, Fiege M, Stenfath M. Agarwal K, Scholz J ycols. Evidence for susceptibility to malignant hyperthermiain patients with exercise-induced rhabdomyolisis.Anesthesiology. 2001; 94: 95-100.9. Denborough M, Lovell R. Anesthesic deaths in a family(letter). Lancet. 1960; 2: 45.10. Nelson TE, Fleweller E. The malignant hyperthermiaSyndrome. New Engl J Med. 1983; 309: 416-18.11. Sambuughin N, Sei Y, Gallagher K, Wyre H, Madsen Dy cols. North American malignant hyperthermiapopulation: Screening of the ryanodine receptor gene andidentification of novel mutations. Anesthesiology 2001; 95:594-9.12. Golinski M. Malignant hyperthermia : A review. PlasticSurg-Nurs. 1995;15:30-3.13. Schulman S. Malignant hyperthemia and pediatricanesthesia. Semin Anesth. 1993;12: 54-64.14. Heiman-Pattersohn T, Natter H, Rosenberg H y cols.Malignant hyperthermia susceptibility in X-linked muscledistrophies. Pediatric Neurol 1987; 2: 356.15. Jonhson C, Edelman K. Malignant hyperthermia: Areview. J perinatol 1992;12(1): 61-71.16. Levitt R. Prospects for the diagnosis of malignanthyperthermia susceptibility using molecular geneapproaches.Anesthesiology 1992; 76:1039-48.17. Illes D, Lehmann-Horn F, Scherer S, Tsui L, WeghuisD y cols.Localisation of the gene encoding the a2/ d -subunits of the L – type voltage dependent calcium channelto chromosome 7q and analysis of the segregation offlanking markers in malignant hyperthermia susceptiblefamilies. Hum Mol Genet 1994; 3: 969-75.18. Mc Carthy T, Healy J, Heffron J Lehane M Deufel T ycols. Localisation of the malignant hyperthermiasusceptibility locus to human chromosome 17q 12-13.2.Nature. 1990; 343: 562-4.19. Manning B, Quane K, Ording H, Urwyler A, TegazzinV y cols. Identification of novel mutations in the ryanodinereceptorgene (RYR1) in malignant hyperthermia:Genotype-Phenotype correlation. Am J Hum Genet. 1998;62: 599-609.20. Olckers A, Meyers D, Meyers S, Taylor E, Fletcher J ycols. Adult muscle sodium channel a– subunit is a genecandidate for malignant hyperthermia susceptibility.Genomics 1992;14: 829-31.21. Sudbrack R, Procaccio V, Klausnitzer M, Curran J,Monsieurs K y cols. Mapping of a further malignanthyperthemia susceptibility locus to chromosome 3q 13.1.Am J Hum Genet 1995; 56: 684-91.22. Robinson R, Monnier N Wolz W, Jung M, Reis A ycols. A genome wide search for susceptibility loci in threeEuropean malignant hyperthermia pedigrees. Hum MolGenet 1997; 6: 953-61.23. Urwyler A, Deufel T, McCarthy T, West S. Guidelinesfor molecular genetic detection of susceptibility tomalignant hyperthermia. Br J Anaesth 2001; 86(2): 283-7.24. Robinson R, Curran J, ellis F Halsall J, May W y cols.Múltiple interacting gene products may influencesusceptibility to malignant hyperthermia. Ann Hum Genet2000; 64: 307-20.25. Stenberg W. Tens-induced pain control in malignanthyperthermia-susceptible patient. Anesth Prog 1994;41(4):100-1.26. Campos JM. Hipertermia maligna. Rev.Esp AnestesiolReanim 1989; 36: 223-39.27. Littleford J, Patel L, Bose D, Cameron C, McKillopC. Masseter muscle spasm in children: Implications ofcontinuing the triggering anesthesic. Anesth Analg 1991;72:151-60.28. Larach M, Rosenberg H, Larach D, Broenle A.Prediction of malignant hyperthermia susceptibility byclinical signs. Anesthesiology 1987; 66: 547-50.29. Larach M, Localio R, Allen G, Denborough M, EllisR, Gronert G y cols. A clinical grading scale to predictmalignant hyperthermia susceptibility. Anesthesiology1994; 80: 771-9.30. Struebing VL. Differential diagnosis of malignanthyperthermia: A case report. J American Assoc NursAnesth 1995; 63: 455-60.31. Rosenberg H, Antognigni J, Muldoon S. Testing formalignant hyperthermia. Anesthesiology 2002; 96: 232-7.32. Ellis F, Harriman D, Keaney J y cols. Halothaneinducedmuscle contracture as a cause of hyperpyrexia.Br J Anaesth 1971; 43: 721-2.33. Kalow W, Britt B, Terreau M, Haist C. Metabolic errorof muscle metabolism after recovery from malignanthyperthermia. Lancet 1970; 2: 895-8.34. Wappler F, Roewer N, Kochling A y cols. In vitro diagnosisof malignant hyperthermia eptibility with ryanodineinduced contractures in human skeletal muscles. AnesthAnalg 1996; 82:1230-6.35. Bendahan D, Kozak-Ribbens G, Rodet C y cols.Phosphorous magnetic resonance spectroscopycharacterization of muscular metabolic anomalies inpatients with malignant hyperthermia. Anesthesiology.1998; 88: 96-107.36. Keblin D, Chortkoff B, Carter M y cols.Polihalogenated and perfluorinated compounds thatdisobey the Meyer-Overton hypothesis. Anesth Analg1994;79:1043-8.37. Ward A, Chaffman M, Sorking E. Dantrolene: A reviewof its pharmacodynamic and pharmacokinetic propertiesand therapeutic use in malignant hyperthermia, theneuroleptic malignant syndrome and an update of its usein muscle apasticity. Drugs 1986; 32:130-68.38. Van Winkle W. Calcium release from skeletal musclesarcoplasmic reticulum: Site of action of dantrolenesodium. Science 1976;193:1130-1.39. Ohnishi S, Taylor S, Gronert G. Calcium-induced Ca +2release from sarcoplasmic reticulum of pigs susceptibleto malignant hyperthermia: The effects of halothane anddantrolene. FEBS Lett. 1983;161:103-7.40. Harrison G. Dantrolene dynamics and kinetics. Br JAnaesth 1988; 60: 279-86.41. Rubin A, Zablocki A. Hyperkalemia, verapamil anddantrolene. Anesthesiology 1987; 66: 246-9.42. Fruen B, Mickelson J, Louis Ch. Dantrolene inhibitionof sarcoplasmic reticulum Ca +2 release by direct andspecific action at skeletal muscle ryanodine receptors. JBiol Chem 1997; 272: 26965-71.43. Nelson T, Liu M, Zapata-Sudo G, Sudo T. Dantrolenesodium can increase or attenuate activity of skeletal muscleryanodine receptor calcium releasechannel.Anesthesiology 1996; 84:1368-79.36